Company: Breakpoint Therapeutics
Job title: Co-Managing Director
Dr. Daniel Speidel is Managing Director and co-founder of Breakpoint Therapeutics GmbH, a Hamburg-based company dedicated to the discovery of anti-cancer drugs that target the DNA Damage Response (DDR) in cancer cells. Prior to commencing his role at Breakpoint he was the Vice President Initiative Leader Oncology at Evotec where his main task was to facilitate formation of a spin-off company that became Breakpoint. Dr. Speidel is a biochemist by training and has more than 20 years’ experience in cancer research focusing on cellular DNA damage responses and p53 in particular. Before joining Evotec he led an academic group at Children’s Medical Research Institute/University of Sydney. A former management consultant with McKinsey & Company, he has also advised several research-related organizations and other institutions on matters of strategic importance.
Panel Discussion: What is the Role of DDR-targeted Therapies in the Wider Oncology Portfolio? 4:45 pm
day: Day Two